首页|依折麦布联合比索洛尔对冠心病介入治疗患者心功能水平及炎症因子的影响

依折麦布联合比索洛尔对冠心病介入治疗患者心功能水平及炎症因子的影响

扫码查看
目的:研究依折麦布联合比索洛尔对冠心病介入治疗患者心功能水平及炎症因子的影响.方法:选取 2020年 3 月至 2023年 3 月于我院行介入治疗的 150 例冠心病患者,采用随机数字法分为对照组、联合组,各 75 例.对照组采用比索洛尔治疗,联合组采用依折麦布联合比索洛尔治疗.比较两组临床疗效、治疗前、治疗4 w后心功能指标、血脂水平[高密度脂蛋白胆固醇(High-density lipoprotein-cholesterol,HDL-C)、低密度脂蛋白胆固醇(Low-density lipoprotein cholesterol,LDL-C)、三酰甘油(Triacylglycerol,TG)、总胆固醇(Total cholesterol,TC)]、血清细胞因子水平、不良反应.结果:联合组临床总有效率高于对照组(P<0.05);治疗 4 w后联合组心功能指标高于对照组(P<0.05);治疗 4 w后联合组HDL-C水平高于对照组,LDL-C、TG、TC水平均低于对照组(P<0.05);治疗4 w后联合组血清细胞因子水平均低于对照组(P<0.05);两组不良反应总发生率差异无统计学意义.结论:依折麦布联合比索洛尔治疗冠心病介入治疗患者疗效显著,可有效改善心功能,调节血脂水平,缓解炎症反应,且不显著增加不良反应.
Effects of Ezetimibe combined with Bisoprolol on cardiac function and inflammatory factors in patients with coronary heart disease after interventional therapy
Objective:To investigate the effects of ezetimibe combined with Bisoprolol on cardiac function and inflammatory factors in patients with coronary heart disease after interventional therapy.Methods:150 patients with coronary artery disease who underwent interventional therapy in our hospital from March 2020 to March 2023 were randomized and digitally divided into the control group and the combined group,75 cases in each group.The control group was treated with bisoprolol,and the combined group was treated with ezetimibe combined with bisoprolol.The clinical efficacy,cardiac function indexes,lipid levels[High-density lipoprotein-cholesterol(HDL-C),Low-density lipoprotein cholesterol(LDL-C),Triacylglycerol(Triacylglycerol(TG),Total cholesterol(TC)],serum cytokines levels,and adverse reactions were compared between the two groups before and after 4 weeks of treatment.Results:The total clinical effective rate of the combined group was higher than that of the control group(P<0.05);the cardiac function indexes of the combined group were higher than those of the control group after 4 weeks of treatment(P<0.05);the HDL-C level of the combined group was higher than that of the control group,and the levels of LDL-C,TG,and TC were lower than those of the control group after 4 weeks of treatment(P<0.05);and the serum cytokine levels of the combined group were lower than those of the control group after 4 weeks of treatment(P<0.05);the difference in the total incidence of adverse reactions between the two groups was not statistically significant.Conclusion:Ezetimibe combined with Bisoprolol is effective in the treatment of patients with coronary artery disease after interventional therapy,which can effectively improve cardiac function,regulate lipid levels,relieve inflammation and do not significantly increase adverse reactions.

EzetimibeBisoprololCoronary heart diseaseCardiac function

张亚利、李小静、牛艳菲

展开 >

平顶山市第一人民医院心血管内科一病区,河南 平顶山 467000

河南省人民医院超声科,郑州大学人民医院,河南 郑州 455000

依折麦布 比索洛尔 冠心病 心功能

2024

四川生理科学杂志
四川省生理科学会

四川生理科学杂志

影响因子:0.575
ISSN:1671-3885
年,卷(期):2024.46(3)
  • 15